@article{ac2c21d3c633434da940956f24311c3f,
title = "Longitudinal assessment of interstitial lung disease in single lung transplant recipients with scleroderma",
abstract = "Objective: To investigate the natural history of fibrotic lung disease in recipients of a single lung transplant for scleroderma-associated interstitial lung disease (ILD). Methods: Global ILD (including ground glass, nodular opacities and fibrosis) was categorized into severity quintiles on first and last post-transplant CT scans, and percent fibrosis by manual contouring was also determined, in nine single lung transplant recipients. Quantitative mean lung densities and volumes for the native and allograft lungs were also acquired. Results: In the native lung, global ILD severity quintile worsened in two cases and percent fibrosis worsened in four cases (range 5-28%). In the lung allograft, one case each developed mild, moderate and severe ILD; of these, new fibrotic ILD (involving <10% of lung) occurred in two cases and acute cellular rejection occurred in one. The average change in native lung density over time was +2.2 Hounsfield Units per year and lung volume +1.4 ml per year, whereas the allograft lung density changed by -5.5 Hounsfield Units per year and total volume +27 ml per year (P = 0.011 and P = 0.039 for native vs allograft density and volume comparisons, respectively). Conclusions: While the course of ILD in the native and transplanted lungs varied in this series, these cases illustrate that disease progression is common in the native lung, suggesting that either the immune process continues to target autoantigens or ongoing fibrotic pathways are active in the native lung. Mild lung disease may occur in the allograft after several years due to either allograft rejection or recurrent mild ILD.",
keywords = "CT imaging, Interstitial lung disease, Longitudinal, Lung transplant, Pulmonary fibrosis, Scleroderma, Systemic sclerosis",
author = "Hinze, {Alicia M.} and Lin, {Cheng T.} and Hussien, {Amira F.} and Jamie Perin and Aida Venado and Golden, {Jeffrey A.} and Francesco Boin and Brown, {Robert H.} and Wise, {Robert A.} and Wigley, {Fredrick M.}",
note = "Funding Information: Funding: Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number T32AR048522 (A.M.H.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research reported in this publication was also supported by the Scleroderma Research Foundation (F.M.W.) and the Martha McCrory Professorship (F.M.W.). Funding Information: Disclosure statement: R.A.W. reports grants and personal fees from AstraZeneca/Medimmune, grants and personal fees from Boehringer Ingelheim, personal fees from Contrafect, personal fees from Pulmonx, personal fees from Roche/Genentech, personal fees from Spiration, personal fees from Sunovion, grants from Pearl Therapeutics, personal fees from Merck, personal fees from Circassia, personal fees from Pneuma, personal fees from Verona, personal fees from Bonti, personal fees from Denali, personal fees from Aradigm, personal fees from Mylan, personal fees from Theravance, personal fees from Propeller Health, personal fees from Kiniksa, personal fees from Syneos, grants and personal fees from Sanofi/Regeneron, and grants and personal fees from GlaxoSmithKline, outside the submitted work. The other authors have declared no conflicts of interest. Publisher Copyright: {\textcopyright} 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.",
year = "2020",
month = apr,
day = "1",
doi = "10.1093/rheumatology/kez341",
language = "English (US)",
volume = "59",
pages = "790--798",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "4",
}